Molecular genetics of prostate cancer: new prospects for old challenges.
暂无分享,去创建一个
[1] E. Montgomery,et al. NKX3.1 as a Marker of Prostatic Origin in Metastatic Tumors , 2010, The American journal of surgical pathology.
[2] Jiaoti Huang,et al. Identification of a Cell of Origin for Human Prostate Cancer , 2010, Science.
[3] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[4] Martin J. Aryee,et al. Androgen-induced TOP2B mediated double strand breaks and prostate cancer gene rearrangements , 2010, Nature Genetics.
[5] M. Ittmann,et al. Dicer Ablation Impairs Prostate Stem Cell Activity and Causes Prostate Atrophy , 2010, Stem cells.
[6] Francesca Demichelis,et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma , 2010, Nature Medicine.
[7] R. Silverman,et al. The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome , 2010, Nature Reviews Urology.
[8] P. Pandolfi,et al. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology , 2010, Nature.
[9] David E. Williams,et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. , 2010, Cancer cell.
[10] M. Loda,et al. A constitutively activated form of the p110β isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice , 2010, Proceedings of the National Academy of Sciences.
[11] Zhaohui S. Qin,et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.
[12] A. D. De Marzo,et al. The role of PI 3‐kinase p110β in AKT signally, cell survival, and proliferation in human prostate cancer cells , 2010, The Prostate.
[13] A. Malek,et al. ETS Transcription Factors Control Transcription of EZH2 and Epigenetic Silencing of the Tumor Suppressor Gene Nkx3.1 in Prostate Cancer , 2010, PloS one.
[14] C. Bieberich,et al. Epithelial and Mesenchymal Cell Biology Loss of Nkx 3 . 1 Expression in Bacterial Prostatitis A Potential Link Between Inflammation and Neoplasia , 2010 .
[15] J. Humm,et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.
[16] E. Gelmann,et al. NKX3.1 activates cellular response to DNA damage. , 2010, Cancer research.
[17] M. Loda,et al. Identification of the miR-106b~25 MicroRNA Cluster as a Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its Host Gene MCM7 in Transformation , 2010, Science Signaling.
[18] P. Pandolfi,et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence , 2010, Nature.
[19] Clifford A. Meyer,et al. Nucleosome Dynamics Define Transcriptional Enhancers , 2010, Nature Genetics.
[20] Rameen Beroukhim,et al. An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB , 2010, Nature Medicine.
[21] A. D'Amico,et al. American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.
[22] J. Clohessy,et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. , 2010, The Journal of clinical investigation.
[23] D. Bonci,et al. MicroRNAs and prostate cancer. , 2010, Endocrine-related cancer.
[24] C. Bieberich,et al. MYC Overexpression Induces Prostatic Intraepithelial Neoplasia and Loss of Nkx3.1 in Mouse Luminal Epithelial Cells , 2010, PloS one.
[25] J. Carpten,et al. Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans , 2010, The Prostate.
[26] M. Morse,et al. A year of successful cancer vaccines points to a path forward. , 2010, Current opinion in molecular therapeutics.
[27] J. Epstein. An update of the Gleason grading system. , 2010, The Journal of urology.
[28] A. Taille,et al. Urine biomarkers in prostate cancer , 2010, Nature Reviews Urology.
[29] Hongling Liao,et al. Long-range enhancers on 8q24 regulate c-Myc , 2010, Proceedings of the National Academy of Sciences.
[30] S. Memarzadeh,et al. Basal epithelial stem cells are efficient targets for prostate cancer initiation , 2010, Proceedings of the National Academy of Sciences.
[31] O. Franco,et al. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma , 2010, Oncogene.
[32] Wei Keat Lim,et al. The transcriptional network for mesenchymal transformation of brain tumors , 2009, Nature.
[33] S. Hayward,et al. Functional Remodeling of Benign Human Prostatic Tissues In Vivo by Spontaneously Immortalized Progenitor and Intermediate Cells , 2009, Stem cells.
[34] H. Bonkhoff,et al. From pathogenesis to prevention of castration resistant prostate cancer , 2010, The Prostate.
[35] Jie Zhang,et al. Nuclear Receptor-Induced Chromosomal Proximity and DNA Breaks Underlie Specific Translocations in Cancer , 2009, Cell.
[36] C. Cooper,et al. Steroid hormone receptors in prostate cancer: a hard habit to break? , 2009, Cancer cell.
[37] S. Varambally,et al. Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer , 2009, Science.
[38] O. Witte,et al. Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. , 2009, Cancer research.
[39] J. Visvader,et al. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. , 2009, Genes & development.
[40] E. Casanova,et al. A Probasin‐MerCreMer BAC allows inducible recombination in the mouse prostate , 2009, Genesis.
[41] W. Isaacs,et al. TMPRSS2–ERG gene fusion status in minute (minimal) prostatic adenocarcinoma , 2009, Modern Pathology.
[42] R. Hauke,et al. Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate , 2009, British Journal of Cancer.
[43] Lin Lin,et al. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. , 2009, Cancer cell.
[44] H. Scher,et al. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. , 2009, The Lancet. Oncology.
[45] Ali Amin Al Olama,et al. Multiple loci on 8q24 associated with prostate cancer susceptibility , 2009, Nature Genetics.
[46] Ali Amin Al Olama,et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study , 2009, Nature Genetics.
[47] Kari Stefansson,et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility , 2009, Nature Genetics.
[48] Peter Kraft,et al. Identification of a new prostate cancer susceptibility locus on chromosome 8q24 , 2009, Nature Genetics.
[49] Robert Schlaberg,et al. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors , 2009, Proceedings of the National Academy of Sciences.
[50] S. Koul,et al. Oxidative stress in prostate cancer. , 2009, Cancer letters.
[51] Dirk F Moore,et al. Outcomes of localized prostate cancer following conservative management. , 2009, JAMA.
[52] S. Morrison,et al. Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution , 2009, Cell.
[53] W. Bushman,et al. The Sonic Hedgehog Pathway Stimulates Prostate Tumor Growth by Paracrine Signaling and Recaptures Embryonic Gene Expression in Tumor Myofibroblasts , 2009, Oncogene.
[54] M. Loda,et al. Differential p53-Independent Outcomes of p19Arf Loss in Oncogenesis , 2009, Science Signaling.
[55] M. Shen,et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer , 2009, Nature.
[56] E. Platz,et al. Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. , 2009, Current opinion in pharmacology.
[57] B. Trock,et al. Individual and cumulative effect of prostate cancer risk‐associated variants on clinicopathologic variables in 5,895 prostate cancer patients , 2009, The Prostate.
[58] W. Gerald,et al. NF-kappaB regulates androgen receptor expression and prostate cancer growth. , 2009, The American journal of pathology.
[59] F. Saad,et al. PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer , 2009, The Journal of pathology.
[60] H. Scher,et al. Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer , 2009, Clinical Cancer Research.
[61] D. Reich,et al. Functional Enhancers at the Gene-Poor 8q24 Cancer-Linked Locus , 2009, PLoS genetics.
[62] M. Teitell,et al. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells , 2009, Proceedings of the National Academy of Sciences.
[63] Clifford A. Meyer,et al. Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer , 2009, Cell.
[64] P. Kantoff,et al. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. , 2009, Cancer research.
[65] S. Abdulkadir,et al. Interactions between Cells with Distinct Mutations in c-MYC and Pten in Prostate Cancer , 2009, PLoS genetics.
[66] Jeffrey M. Rosen,et al. The Increasing Complexity of the Cancer Stem Cell Paradigm , 2009, Science.
[67] P. Humphrey,et al. Loss-of-Nkx3.1 Leads to Activation of Discrete Downstream Target Genes during Prostate Tumorigenesis , 2009, Oncogene.
[68] Mustafa Ozen,et al. Global Gene Expression Analysis of Reactive Stroma in Prostate Cancer , 2009, Clinical Cancer Research.
[69] D. Olmos,et al. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. , 2009, Cancer research.
[70] A. D. De Marzo,et al. Epigenetic alterations in human prostate cancers. , 2009, Endocrinology.
[71] M. D. Anway,et al. Gene expression changes are age‐dependent and lobe‐specific in the brown Norway rat model of prostatic hyperplasia , 2009, The Prostate.
[72] T. H. van der Kwast,et al. Accumulating Progenitor Cells in the Luminal Epithelial Cell Layer Are Candidate Tumor Initiating Cells in a Pten Knockout Mouse Prostate Cancer Model , 2009, PloS one.
[73] C. Takimoto,et al. Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes , 2009, Clinical Cancer Research.
[74] S. Dhanasekaran,et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. , 2009, Cancer research.
[75] H. Scher,et al. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.
[76] C. Tepper,et al. MicroRNAs and their potential for translation in prostate cancer. , 2009, Urologic oncology.
[77] C. Sander,et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis , 2009, Nature Genetics.
[78] Pier Paolo Pandolfi,et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.
[79] G. Prins,et al. The role of Wnt5a in prostate gland development. , 2009, Developmental biology.
[80] Myles Brown,et al. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. , 2009, Cancer research.
[81] Jun Luo,et al. Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer , 2009, Nature Medicine.
[82] Zhiyong Guo,et al. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. , 2009, Cancer cell.
[83] Carmela Conte,et al. Oxidative stress-related aging: A role for prostate cancer? , 2009, Biochimica et biophysica acta.
[84] D. Dearnaley,et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. , 2009, Cancer research.
[85] Oscar Lin,et al. Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer , 2009, Clinical Cancer Research.
[86] Zhiyong Guo,et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.
[87] E. Gelmann,et al. NKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferation. , 2009, Cancer research.
[88] David M. Sabatini,et al. Tumours with PI3K activation are resistant to dietary restriction , 2009, Nature.
[89] Yi Qu,et al. Genome-Wide Profiling of Histone H3 Lysine 4 and Lysine 27 Trimethylation Reveals an Epigenetic Signature in Prostate Carcinogenesis , 2009, PloS one.
[90] Madhuchhanda Bhattacharjee,et al. Conserved gene expression programs integrate mammalian prostate development and tumorigenesis. , 2009, Cancer research.
[91] Todd M Morgan,et al. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. , 2009, Current cancer drug targets.
[92] R. Matusik,et al. Activation of β‐Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration , 2009, The Prostate.
[93] M. Karin,et al. Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin , 2009, Nature.
[94] J. Céraline,et al. Pleiotropic functional properties of androgen receptor mutants in prostate cancer , 2009, Human mutation.
[95] K. Polyak,et al. Cancer stem cells: a model in the making. , 2009, Current opinion in genetics & development.
[96] G. Evan,et al. Cellular senescence: hot or what? , 2009, Current opinion in genetics & development.
[97] John T. Wei,et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.
[98] D. Guertin,et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. , 2009, Cancer cell.
[99] J. Crowley,et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). , 2009, JAMA.
[100] H. Fuse,et al. Neuroendocrine differentiation in the progression of prostate cancer , 2009, International journal of urology : official journal of the Japanese Urological Association.
[101] A. Clarke,et al. K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. , 2009, Cancer research.
[102] R. Vessella,et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.
[103] O. Witte,et al. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics , 2008, Proceedings of the National Academy of Sciences.
[104] L. Chin,et al. BRAF Activation Initiates but Does Not Maintain Invasive Prostate Adenocarcinoma , 2008, PloS one.
[105] S. Varambally,et al. Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.
[106] K. Leong,et al. Generation of a prostate from a single adult stem cell , 2008, Nature.
[107] S. Dhanasekaran,et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer , 2008, Oncogene.
[108] G Parmigiani,et al. Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer , 2008, Oncogene.
[109] Mark A Rubin,et al. Evaluating localized prostate cancer and identifying candidates for focal therapy. , 2008, Urology.
[110] P. Verhagen,et al. An activating mutation in AKT1 in human prostate cancer , 2008, International journal of cancer.
[111] Gang Wang,et al. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. , 2008, Cancer research.
[112] P. Clark,et al. Chemokine Markers Predict Biochemical Recurrence of Prostate Cancer following Prostatectomy , 2008, Clinical Cancer Research.
[113] Mauro Biffoni,et al. The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities , 2008, Nature Medicine.
[114] S. Morrison,et al. Efficient tumor formation by single human melanoma cells , 2008, Nature.
[115] M. Ittmann,et al. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. , 2008, Cancer research.
[116] J. Visvader,et al. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.
[117] W. Sellers,et al. Drug discovery approaches targeting the PI3K/Akt pathway in cancer , 2008, Oncogene.
[118] W. Gerald,et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. , 2008, The Journal of clinical investigation.
[119] E. Gelmann,et al. Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1. , 2008, Cancer research.
[120] Jun Luo,et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis , 2008, Modern Pathology.
[121] S. Yeh,et al. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages , 2008, Proceedings of the National Academy of Sciences.
[122] Jorge Yao,et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer , 2008, Proceedings of the National Academy of Sciences.
[123] W. Gerald,et al. Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. , 2008, Genes & development.
[124] S. Kasper,et al. Stem cells: The root of prostate cancer? , 2008, Journal of cellular physiology.
[125] I. Mills,et al. Alterations in β‐catenin expression and localization in prostate cancer , 2008, The Prostate.
[126] Chen Sun,et al. Delineation of TMPRSS2-ERG Splice Variants in Prostate Cancer , 2008, Clinical Cancer Research.
[127] R. Stephens,et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. , 2008, Cancer research.
[128] M. Gleave,et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.
[129] Daniel B. Martin,et al. Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.
[130] M. Day,et al. The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis , 2008, Oncogene.
[131] B. Trask,et al. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. , 2008, Cancer research.
[132] B. Timms. Prostate development: a historical perspective. , 2008, Differentiation; research in biological diversity.
[133] P. Nelson,et al. Gene expression profiling in the developing prostate. , 2008, Differentiation; research in biological diversity.
[134] G. Prins,et al. Molecular signaling pathways that regulate prostate gland development. , 2008, Differentiation; research in biological diversity.
[135] O. Franco,et al. Gene targeting to the stroma of the prostate and bone. , 2008, Differentiation; research in biological diversity.
[136] G. Cunha. Mesenchymal-epithelial interactions: past, present, and future. , 2008, Differentiation; research in biological diversity.
[137] F. D. D. Fagagna. Living on a break: cellular senescence as a DNA-damage response , 2008, Nature Reviews Cancer.
[138] E. Gelmann,et al. R E V Ie W a Rt I C L E , 2022 .
[139] D. Tindall,et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.
[140] M. Loda,et al. Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis , 2008, Nature.
[141] John T. Wei,et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. , 2008, Cancer cell.
[142] N. Maitland,et al. Prostate cancer stem cells: a new target for therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[143] Ian A. White,et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. , 2008, The Journal of clinical investigation.
[144] D. Gold,et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation , 2008, Nature Genetics.
[145] J. Ting,et al. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. , 2008, Genes & development.
[146] T. Tammela,et al. TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis , 2008, Clinical Cancer Research.
[147] M. Loda,et al. Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications , 2008, Clinical Cancer Research.
[148] P. Nelson,et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.
[149] A. Strasser,et al. Is tumor growth sustained by rare cancer stem cells or dominant clones? , 2008, Cancer research.
[150] R. Shah,et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. , 2008, Cancer research.
[151] M. Parker,et al. Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression , 2008, Oncogene.
[152] Pier Paolo Pandolfi,et al. Tenets of PTEN Tumor Suppression , 2008, Cell.
[153] R. Silverman,et al. Inflammation, infection, and prostate cancer , 2008, Current opinion in urology.
[154] J. Amiel,et al. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data. , 2008, Cancer genetics and cytogenetics.
[155] Hua Tian,et al. A paracrine requirement for hedgehog signalling in cancer , 2008, Nature.
[156] S. Jones,et al. Many roads lead to oncogene-induced senescence , 2008, Oncogene.
[157] M. Shen,et al. Sox9 is required for prostate development. , 2008, Developmental biology.
[158] D. Elashoff,et al. Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model. , 2008, Cancer research.
[159] R. Shah,et al. CHARACTERIZATION OF TMPRSS2-ETS GENE ABERRATIONS IN ANDROGEN INDEPENDENT METASTATIC PROSTATE CANCER , 2008 .
[160] S. Signoretti,et al. p63 in prostate biology and pathology , 2008, Journal of cellular biochemistry.
[161] F. Jirik,et al. Temporally controlled prostate epithelium‐specific gene alterations , 2008, Genesis.
[162] T. Ratliff,et al. Prostate inflammation and its potential impact on prostate cancer: A current review , 2008, Journal of cellular biochemistry.
[163] Andrew J. Vickers,et al. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring , 2008, Nature Reviews Cancer.
[164] J. Cuzick,et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate , 2008, Oncogene.
[165] C. Creighton,et al. Widespread deregulation of microRNA expression in human prostate cancer , 2008, Oncogene.
[166] W. Willett,et al. Multiple loci identified in a genome-wide association study of prostate cancer , 2008, Nature Genetics.
[167] P. Chambon,et al. Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma , 2008, Proceedings of the National Academy of Sciences.
[168] S. Cross,et al. The polycomb group protein EZH2 regulates actin polymerization in human prostate cancer cells , 2008, The Prostate.
[169] W. Isaacs,et al. A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms , 2008, The Prostate.
[170] M. Shen,et al. Role of epithelial cell fibroblast growth factor receptor substrate 2α in prostate development, regeneration and tumorigenesis , 2008, Development.
[171] P. Nelson,et al. A causal role for ERG in neoplastic transformation of prostate epithelium , 2008, Proceedings of the National Academy of Sciences.
[172] R. Shah,et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.
[173] Alastair Droop,et al. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions , 2008, Genome Biology.
[174] Christopher P Evans,et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells , 2007, Proceedings of the National Academy of Sciences.
[175] M. Teitell,et al. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. , 2007, Cancer cell.
[176] Leif E. Peterson,et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. , 2007, Cancer cell.
[177] Oliver Sartor,et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. , 2007, The Journal of urology.
[178] K. Fizazi,et al. The role of Src in prostate cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[179] A. Zlotta,et al. Prostate cancer prevention , 2007, Cancer.
[180] Li Li,et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. , 2007, Genes & development.
[181] B. Aronow,et al. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. , 2007, Cancer research.
[182] M. Kattan,et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. , 2007, Journal of the National Cancer Institute.
[183] R. Schneider-Broussard,et al. Erratum: Hierarchical organization of prostate cancer cells in xenograft tumors: The CD44+α2β1+ cell population is enriched in tumor-initiating cells (Cancer Research (2007) 67, (6796-6805)) , 2007 .
[184] J. Brooks,et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. , 2007, Cancer research.
[185] R. Shah,et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. , 2007, Cancer research.
[186] M. Papotti,et al. Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease. , 2007, The Journal of urology.
[187] A. D. De Marzo,et al. Inflammation, atrophy, and prostate carcinogenesis. , 2007, Urologic oncology.
[188] D. Trump,et al. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.
[189] Ming-Fong Lin,et al. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. , 2007, Endocrine-related cancer.
[190] S. Dhanasekaran,et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.
[191] E. Small,et al. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge®) , 2007, Expert opinion on biological therapy.
[192] O. Witte,et al. Stem cells in prostate cancer initiation and progression. , 2007, The Journal of clinical investigation.
[193] Wei Shi,et al. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. , 2007, Cancer research.
[194] S. Yeh,et al. Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor , 2007, Proceedings of the National Academy of Sciences.
[195] R. Schneider-Broussard,et al. Hierarchical Organization of Prostate Cancer Cells in Xenograft Tumors: The CD44+α2β1+ Cell Population Is Enriched in Tumor-Initiating Cells , 2007 .
[196] M. Shen,et al. Pten inactivation and the emergence of androgen-independent prostate cancer. , 2007, Cancer research.
[197] Mikhail Teverovskiy,et al. Improved prediction of prostate cancer recurrence through systems pathology. , 2007, The Journal of clinical investigation.
[198] H. Zhang,et al. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. , 2007, The Journal of clinical investigation.
[199] Jayoung Kim,et al. Cholesterol sensitivity of endogenous and myristoylated Akt. , 2007, Cancer research.
[200] Shunyou Wang,et al. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. , 2007, Cancer research.
[201] T. Tammela,et al. MicroRNA expression profiling in prostate cancer. , 2007, Cancer research.
[202] F. Ishikawa,et al. Cellular senescence and chromatin structure , 2007, Chromosoma.
[203] Debashis Ghosh,et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer , 2007, Modern Pathology.
[204] M. Rubin,et al. Morphological features of TMPRSS2–ERG gene fusion prostate cancer , 2007, The Journal of pathology.
[205] A. D. De Marzo,et al. Abnormal DNA methylation, epigenetics, and prostate cancer. , 2007, Frontiers in bioscience : a journal and virtual library.
[206] D. Gudbjartsson,et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24 , 2007, Nature Genetics.
[207] P. Fearnhead,et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 , 2007, Nature Genetics.
[208] R. Eeles,et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate , 2007, Oncogene.
[209] David A. Cheresh,et al. Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin , 2007, Nature.
[210] Jianfeng Xu,et al. Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.
[211] A. Whittemore,et al. Multiple regions within 8q24 independently affect risk for prostate cancer , 2007, Nature Genetics.
[212] N. Rosen,et al. Uncoupling of hormone-dependence from chaperone-dependence in the L701H mutation of the androgen receptor , 2007, Molecular and Cellular Endocrinology.
[213] J. Mossong,et al. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis , 2007, International journal of cancer.
[214] J. Resau,et al. Inactivation of Apc in the mouse prostate causes prostate carcinoma. , 2007, Cancer research.
[215] M. Shen,et al. Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis , 2007, Development.
[216] A. D. De Marzo,et al. The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. , 2007, Cancer research.
[217] J. Derisi,et al. An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors , 2007, Proceedings of the National Academy of Sciences.
[218] O. Witte,et al. Isolation and functional characterization of murine prostate stem cells , 2007, Proceedings of the National Academy of Sciences.
[219] P. Humphrey,et al. Diagnosis of adenocarcinoma in prostate needle biopsy tissue , 2007, Journal of Clinical Pathology.
[220] John T. Wei,et al. Integrative molecular concept modeling of prostate cancer progression , 2007, Nature Genetics.
[221] D. Petrylak. New paradigms for advanced prostate cancer. , 2007, Reviews in urology.
[222] C. Sternberg,et al. Current indications for chemotherapy in prostate cancer patients. , 2007, European urology.
[223] A. Evans,et al. Telomere attrition in isolated high-grade prostatic intraepithelial neoplasia and surrounding stroma is predictive of prostate cancer. , 2007, Neoplasia.
[224] D. Schrijvers. Androgen-independent prostate cancer. , 2007, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[225] W. Zhong,et al. Chronic bacterial infection and inflammation incite reactive hyperplasia in a mouse model of chronic prostatitis , 2007, The Prostate.
[226] C. Bieberich,et al. Decreased NKX3.1 Protein Expression in Focal Prostatic Atrophy, Prostatic Intraepithelial Neoplasia, and Adenocarcinoma: Association with Gleason Score and Chromosome 8p Deletion , 2006 .
[227] T. Vomastek,et al. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. , 2006, Cancer research.
[228] O. Kallioniemi,et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. , 2006, Cancer research.
[229] R. Schwartz,et al. Expression of an Nkx3.1‐CRE gene using ROSA26 reporter mice , 2006, Genesis.
[230] Rajiv Dhir,et al. Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. , 2006, The American journal of pathology.
[231] B. Tai,et al. RNASEL Gene Polymorphisms and the Risk of Prostate Cancer: a Meta-analysis , 2006, Clinical Cancer Research.
[232] L. Lessard,et al. Nuclear Localization of Nuclear Factor-κB p65 in Primary Prostate Tumors Is Highly Predictive of Pelvic Lymph Node Metastases , 2006, Clinical Cancer Research.
[233] Jiaoti Huang,et al. Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression , 2006, Modern Pathology.
[234] R. DiPaola,et al. Vitamin D Inhibits the Formation of Prostatic Intraepithelial Neoplasia in Nkx3.1; Pten Mutant Mice , 2006, Clinical Cancer Research.
[235] Zhiyong Guo,et al. Regulation of androgen receptor activity by tyrosine phosphorylation. , 2006, Cancer cell.
[236] W. Gerald,et al. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer , 2006, Proceedings of the National Academy of Sciences.
[237] A. Whittemore,et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men , 2006, Proceedings of the National Academy of Sciences.
[238] J. Tchinda,et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.
[239] Michael Ittmann,et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.
[240] David C. Corney,et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. , 2006, Cancer research.
[241] M. Shen,et al. Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. , 2006, Cancer research.
[242] Leroy Hood,et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[243] Tapio Visakorpi,et al. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late‐stage prostate cancer , 2006, Genes, chromosomes & cancer.
[244] M. Conaway,et al. Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells , 2006, The Prostate.
[245] R. Lipinski,et al. Functional compensation in Hedgehog signaling during mouse prostate development. , 2006, Developmental biology.
[246] P. Pandolfi,et al. p18Ink4c and Pten Constrain a Positive Regulatory Loop between Cell Growth and Cell Cycle Control , 2006, Molecular and Cellular Biology.
[247] M. Gleave,et al. Loss of PTEN is associated with progression to androgen independence , 2006, The Prostate.
[248] R. Cardiff,et al. Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model. , 2006, Neoplasia.
[249] A. Gylfason,et al. A common variant associated with prostate cancer in European and African populations , 2006, Nature Genetics.
[250] E. Hurt,et al. Stem cells in prostate cancer: Resolving the castrate-resistant conundrum and implications for hormonal therapy , 2006, Cancer biology & therapy.
[251] Jason A. Koutcher,et al. Identification of a tumour suppressor network opposing nuclear Akt function , 2006, Nature.
[252] I. Mellinghoff,et al. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[253] M. Gleave,et al. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. , 2006, Cancer cell.
[254] H. Stoop,et al. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi‐allelic gene deletion , 2006, The Journal of pathology.
[255] H. Li,et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells , 2006, Oncogene.
[256] T. Golub,et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.
[257] J. Derisi,et al. Identification of a Novel Gammaretrovirus in Prostate Tumors of Patients Homozygous for R462Q RNASEL Variant , 2006, PLoS pathogens.
[258] R. Hayes,et al. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. , 2006, Journal of the National Cancer Institute.
[259] R. Hill. Identifying cancer stem cells in solid tumors: case not proven. , 2006, Cancer research.
[260] Max S Wicha,et al. Cancer stem cells: an old idea--a paradigm shift. , 2006, Cancer research.
[261] S. Akira,et al. Macrophage/Cancer Cell Interactions Mediate Hormone Resistance by a Nuclear Receptor Derepression Pathway , 2006, Cell.
[262] C. Croce,et al. A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[263] Shunyou Wang,et al. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[264] H. Wu,et al. PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer , 2006, Oncogene.
[265] P. Nelson,et al. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. , 2006, Cancer research.
[266] O. Halvorsen,et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[267] Aubie K. Shaw,et al. Isolation and characterization of an immortalized mouse urogenital sinus mesenchyme cell line , 2005, The Prostate.
[268] T. Sellers,et al. Association between polymorphisms in the DNA repair genes XRCC1 and APE1, and the risk of prostate cancer in white and black Americans. , 2006, The Journal of urology.
[269] P. Pandolfi,et al. p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control. , 2006, Molecular and cellular biology.
[270] T. Owen-Hughes,et al. Nucleosome dynamics. , 2006, Biochemical Society symposium.
[271] Ximing J. Yang,et al. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. , 2006, Genes & development.
[272] C. Sawyers,et al. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. , 2005, Cancer research.
[273] N. Maitland,et al. Prospective identification of tumorigenic prostate cancer stem cells. , 2005, Cancer research.
[274] R. Shah,et al. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro , 2005, Aging cell.
[275] R. Cardiff,et al. Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model. , 2005, Cancer research.
[276] J. Tchinda,et al. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.
[277] Hong Wu,et al. Expression Signature of the Mouse Prostate* , 2005, Journal of Biological Chemistry.
[278] W. Figg,et al. In vivo models of prostate cancer metastasis to bone. , 2005, The Journal of urology.
[279] Anna Frolov,et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. , 2005, Cancer research.
[280] Jason A. Koutcher,et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.
[281] P. Pandolfi,et al. Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. , 2005, Genes & development.
[282] T. DeWeese,et al. Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. , 2005, Cancer research.
[283] R. Caprioli,et al. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation , 2005, Development.
[284] T. Tsuzuki,et al. Immunohistochemical study of chromogranin A in Stage D2 prostate cancer. , 2005, Urology.
[285] K. Tomer,et al. Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer , 2005, Clinical Cancer Research.
[286] T. H. van der Kwast,et al. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. , 2005, Cancer research.
[287] J. Hsieh,et al. Down-regulation of Human DAB2IP Gene Expression Mediated by Polycomb Ezh2 Complex and Histone Deacetylase in Prostate Cancer* , 2005, Journal of Biological Chemistry.
[288] H. Horvitz,et al. MicroRNA expression profiles classify human cancers , 2005, Nature.
[289] D. Moscatelli,et al. Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[290] O. Witte,et al. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[291] Christoph Wülfing,et al. Polycomb Group Protein Ezh2 Controls Actin Polymerization and Cell Signaling , 2005, Cell.
[292] James A Hanley,et al. 20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.
[293] D. Gioeli. Signal transduction in prostate cancer progression. , 2005, Clinical science.
[294] Jayoung Kim,et al. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. , 2005, The Journal of clinical investigation.
[295] J. Cigudosa,et al. Immortalization of primary human prostate epithelial cells by c-Myc. , 2005, Cancer research.
[296] D. Peehl. Primary cell cultures as models of prostate cancer development. , 2005, Endocrine-related cancer.
[297] E. Gelmann,et al. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. , 2005, Cancer research.
[298] M. Sadar,et al. Cell lines used in prostate cancer research: a compendium of old and new lines--part 1. , 2005, The Journal of urology.
[299] M. Sadar,et al. Cell lines used in prostate cancer research: a compendium of old and new lines--part 2. , 2005, The Journal of urology.
[300] N. Joste,et al. Association between cancer-free survival and telomere DNA content in prostate tumors. , 2005, The Journal of urology.
[301] S. Kasper. Survey of genetically engineered mouse models for prostate cancer: Analyzing the molecular basis of prostate cancer development, progression, and metastasis , 2005, Journal of cellular biochemistry.
[302] Zhong Jiang,et al. Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. , 2005, American journal of clinical pathology.
[303] Michael Ittmann,et al. Mutation of the androgen receptor causes oncogenic transformation of the prostate. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[304] J. Kench,et al. Lower levels of nuclear β‐catenin predict for a poorer prognosis in localized prostate cancer , 2005, International journal of cancer.
[305] Rajvir Dahiya,et al. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. , 2005, Journal of the National Cancer Institute.
[306] L. Capasso. Antiquity of cancer , 2005, International journal of cancer.
[307] C. Logothetis,et al. Osteoblasts in prostate cancer metastasis to bone , 2005, Nature Reviews Cancer.
[308] W. Nelson. Prostate cancer prevention , 2007, The Journal of nutrition.
[309] D. Ghosh,et al. Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases , 2004, Cancer Research.
[310] S. Horvath,et al. Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer , 2004, Clinical Cancer Research.
[311] Fred Saad,et al. Nuclear Factor-κB Nuclear Localization Is Predictive of Biochemical Recurrence in Patients with Positive Margin Prostate Cancer , 2004, Clinical Cancer Research.
[312] Yong Lin,et al. A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[313] Ingo K Mellinghoff,et al. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. , 2004, Cancer cell.
[314] H. Grönberg,et al. Genetic Analysis of the RNASEL Gene in Hereditary, Familial, and Sporadic Prostate Cancer , 2004, Clinical Cancer Research.
[315] A. Mills,et al. Role of p63 and basal cells in the prostate , 2004, Development.
[316] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[317] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[318] Chawnshang Chang,et al. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. , 2004, Molecular endocrinology.
[319] D. Hudson,et al. Epithelial stem cells in human prostate growth and disease , 2004, Prostate Cancer and Prostatic Diseases.
[320] J. Isaacs,et al. Enhanced Redundancy in Akt and Mitogen-activated Protein Kinase-induced Survival of Malignant versus Normal Prostate Epithelial Cells , 2004, Cancer Research.
[321] M. Datta,et al. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[322] D. Neal,et al. CD133, a novel marker for human prostatic epithelial stem cells , 2004, Journal of Cell Science.
[323] E. Montgomery,et al. Telomere Length Abnormalities Occur Early in the Initiation of Epithelial Carcinogenesis , 2004, Clinical Cancer Research.
[324] A. Ullrich,et al. The discovery of receptor tyrosine kinases: targets for cancer therapy , 2004, Nature Reviews Cancer.
[325] Daniel J Schaid,et al. The complex genetic epidemiology of prostate cancer. , 2004, Human molecular genetics.
[326] P. Beachy,et al. Roles for Hedgehog signaling in androgen production and prostate ductal morphogenesis. , 2004, Developmental biology.
[327] M. Rubin,et al. Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee , 2004, Cancer Research.
[328] D. Grignon. Unusual subtypes of prostate cancer , 2004, Modern Pathology.
[329] L. Lessard,et al. Expression of NF‐κB in prostate cancer lymph node metastases , 2004 .
[330] A. D. De Marzo,et al. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer , 2004, Journal of cellular biochemistry.
[331] S. Balk,et al. Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence , 2004, Journal of cellular biochemistry.
[332] M. Washington,et al. TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004, Science.
[333] I. Thompson,et al. The Prostate Cancer Prevention Trial: current status. , 2004, The Journal of urology.
[334] R. Tibshirani,et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[335] M. Ittmann,et al. Chronic activity of ectopic type 1 fibroblast growth factor receptor tyrosine kinase in prostate epithelium results in hyperplasia accompanied by intraepithelial neoplasia , 2004, The Prostate.
[336] E. Latulippe,et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. , 2004, The American journal of pathology.
[337] A. Maitra,et al. Urological Survey UROLOGICAL ONCOLOGY: PROSTATE CANCER Hedgehog Signalling in Prostate Regeneration, Neoplasia and Metastasis , 2005 .
[338] R. Vessella,et al. Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.
[339] Jin-Tang Dong. Chromosomal Deletions and Tumor Suppressor Genes in Prostate Cancer , 2004, Cancer and Metastasis Reviews.
[340] J. Hornaday,et al. Cancer Facts & Figures 2004 , 2004 .
[341] O. Grace,et al. Sonic hedgehog regulates prostatic growth and epithelial differentiation. , 2003, Developmental biology.
[342] M. Ittmann,et al. Cooperation between ectopic FGFR1 and depression of FGFR2 in induction of prostatic intraepithelial neoplasia in the mouse prostate. , 2003, Cancer research.
[343] Michael F. Clarke,et al. Applying the principles of stem-cell biology to cancer , 2003, Nature Reviews Cancer.
[344] C. Sawyers. Will mTOR inhibitors make it as cancer drugs? , 2003, Cancer cell.
[345] W. Isaacs,et al. Human prostate cancer precursors and pathobiology. , 2003, Urology.
[346] P. Pandolfi,et al. Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.
[347] J. Carpten,et al. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates. , 2003, Cancer research.
[348] Mustafa Ozen,et al. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. , 2003, Cancer research.
[349] O. Witte,et al. In vivo regeneration of murine prostate from dissociated cell populations of postnatal epithelia and urogenital sinus mesenchyme , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[350] D. Corey,et al. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. , 2003, Cancer research.
[351] T. Graeber,et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. , 2003, Cancer cell.
[352] A. Thomson,et al. FGF-10 plays an essential role in the growth of the fetal prostate. , 2003, Developmental biology.
[353] P. Nelson,et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.
[354] P. Kantoff,et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[355] C. Harley,et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. , 2003, Cancer research.
[356] R. Cardiff,et al. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. , 2003, Cancer research.
[357] J. Schalken,et al. Epithelial cell differentiation in the human prostate epithelium: implications for the pathogenesis and therapy of prostate cancer. , 2003, Critical reviews in oncology/hematology.
[358] E. Gelmann. Searching for the gatekeeper oncogene of prostate cancer. , 2003, Critical reviews in oncology/hematology.
[359] Todd R. Golub,et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[360] Tsuey-Ming Chen,et al. Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model , 2003, The Prostate.
[361] A. Evans,et al. Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma , 2003, Oncogene.
[362] Patricia D. Castro,et al. Cellular senescence in the pathogenesis of benign prostatic hyperplasia , 2003, The Prostate.
[363] W. Isaacs,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Pathological and Molecular Aspects of Prostate Cancer Prostate Cancer Ii , 2022 .
[364] Jeffrey A. Magee,et al. Haploinsufficiency at the Nkx3.1 locus. A paradigm for stochastic, dosage-sensitive gene regulation during tumor initiation. , 2003, Cancer cell.
[365] Rajvir Dahiya,et al. Hormonal, cellular, and molecular control of prostatic development. , 2003, Developmental biology.
[366] N. Greenberg,et al. Models of metastatic prostate cancer: a transgenic perspective , 2003, Prostate Cancer and Prostatic Diseases.
[367] Mitchell D Schnall,et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. , 2002, Cancer cell.
[368] B. Foster,et al. Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. , 2002, Differentiation; research in biological diversity.
[369] J. Witte,et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases , 2002, Nature Genetics.
[370] J. Hicks,et al. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. , 2002, Cancer research.
[371] S. Dhanasekaran,et al. The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.
[372] W. Bushman,et al. Sonic hedgehog activates mesenchymal Gli1 expression during prostate ductal bud formation. , 2002, Developmental biology.
[373] R. Cardiff,et al. Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. , 2002, Cancer research.
[374] C. Foster,et al. Prostatic stem cells , 2002, The Journal of pathology.
[375] R. Vessella,et al. Establishment and characterization of osseous prostate cancer models: Intra‐tibial injection of human prostate cancer cells , 2002, The Prostate.
[376] R. Cardiff,et al. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. , 2002, Cancer research.
[377] Jing Ma,et al. Occurrence of NKX3.1 C154T polymorphism in men with and without prostate cancer and studies of its effect on protein function. , 2002, Cancer research.
[378] J. Trent,et al. α-methylacyl-CoA racemase: A new molecular marker for prostate cancer , 2002 .
[379] D. Troyer,et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[380] Peter A. Humphrey,et al. Conditional Loss of Nkx3.1 in Adult Mice Induces Prostatic Intraepithelial Neoplasia , 2002, Molecular and Cellular Biology.
[381] E. Lander,et al. Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.
[382] R. Cardiff,et al. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[383] D. Bostwick,et al. Determination of a minimal deletion interval on chromosome band 8p21 in sporadic prostate cancer † , 2002, Genes, chromosomes & cancer.
[384] K. Klinger,et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1 , 2002, Nature Genetics.
[385] M. Egorin,et al. Androgen-Independent Prostate Cancer , 2002 .
[386] R. V. van Breemen,et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. , 2001, Journal of the National Cancer Institute.
[387] S. Hayward,et al. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. , 2001, Cancer research.
[388] I. Weissman,et al. Stem cells, cancer, and cancer stem cells , 2001, Nature.
[389] I. Leav,et al. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[390] C. Korch,et al. TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. , 2001, Cancer research.
[391] J. Isaacs,et al. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. , 2001, Cancer research.
[392] R L Vessella,et al. Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .
[393] E. Petricoin,et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.
[394] D. Ornstein,et al. Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium. , 2001, The Journal of urology.
[395] J. Carpten,et al. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. , 2001, American journal of human genetics.
[396] L. Marnett,et al. Oxidative stress in chemoprevention trials. , 2001, Urology.
[397] M. Kelley,et al. Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[398] Jianfeng Xu,et al. Linkage of prostate cancer susceptibility loci to chromosome 1 , 2001, Human Genetics.
[399] P. Chaurand,et al. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. , 2001, Cancer research.
[400] K. Pienta,et al. VCaP, a cell-based model system of human prostate cancer. , 2001, In vivo.
[401] P. Roy-Burman,et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation , 2001, Mechanisms of Development.
[402] P. Pandolfi,et al. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse , 2001, Nature Genetics.
[403] R. Dahiya,et al. Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system , 2001, Cell Death and Differentiation.
[404] L. Kolonel. Fat, meat, and prostate cancer. , 2001, Epidemiologic reviews.
[405] O. Kallioniemi,et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. , 2000, Cancer research.
[406] R. Cardiff,et al. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. , 2000, Cancer research.
[407] A. Bilancio,et al. Steroid‐induced androgen receptor–oestradiol receptor β–Src complex triggers prostate cancer cell proliferation , 2000, The EMBO journal.
[408] N. Copeland,et al. Nkx3.1, a murine homolog of Drosophila bagpipe, regulates epithelial ductal branching and proliferation of the prostate and palatine glands , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.
[409] M. Shen,et al. Molecular genetics of prostate cancer. , 2000, Genes & development.
[410] A. Whittemore,et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[411] M. Benson,et al. Expression of senescence-associated beta-galactosidase in enlarged prostates from men with benign prostatic hyperplasia. , 2000, Urology.
[412] D. Bostwick,et al. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer , 2000, Cancer.
[413] L. Chung,et al. LNCaP progression model of human prostate cancer: Androgen‐independence and osseous metastasis , 2000, The Prostate.
[414] H. Arnold,et al. Targeted disruption of the Nkx3.1 gene in mice results in morphogenetic defects of minor salivary glands: parallels to glandular duct morphogenesis in prostate , 2000, Mechanisms of Development.
[415] Donna M. Peehl,et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor , 2000, Nature Medicine.
[416] H. Moch,et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.
[417] P. Hein,et al. Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium , 2000, Breast Cancer Research.
[418] J. Epstein,et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. , 1999, The American journal of pathology.
[419] A. Belldegrun,et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. , 1999, Cancer research.
[420] D. Bostwick,et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. , 1999, Journal of the National Cancer Institute.
[421] M. Loda,et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.
[422] L. Chin,et al. Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.
[423] M. T. Abreu-Martin,et al. Mitogen-Activated Protein Kinase Kinase Kinase 1 Activates Androgen Receptor-Dependent Transcription and Apoptosis in Prostate Cancer , 1999, Molecular and Cellular Biology.
[424] J. Clemens,et al. Prostate development requires Sonic hedgehog expressed by the urogenital sinus epithelium. , 1999, Developmental biology.
[425] R. Cardiff,et al. Roles for Nkx3.1 in prostate development and cancer. , 1999, Genes & development.
[426] Noah Craft,et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.
[427] C. Cordon-Cardo,et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[428] H. Frierson,et al. Activation of mitogen-activated protein kinase associated with prostate cancer progression. , 1999, Cancer research.
[429] Jeremy Fairbank,et al. Historical Perspective , 1987, Do We Really Understand Quantum Mechanics?.
[430] Desok Kim,et al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. , 1998, Cancer research.
[431] D. Bostwick,et al. Independent origin of multiple foci of prostatic intraepithelial neoplasia , 1998, Cancer.
[432] M. Diaz,et al. Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN). , 1998, The Journal of urology.
[433] F. Collins,et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. , 1998, Nature Genetics.
[434] Carlos Cordon-Cardo,et al. Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.
[435] R. Vessella,et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[436] M. Ittmann,et al. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[437] N. Maitland,et al. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. , 1998, Cancer research.
[438] M. Kattan,et al. Androgen-independent prostate cancer progression in the TRAMP model. , 1997, Cancer research.
[439] M. Augustus,et al. Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. , 1997, Cancer research.
[440] J. Macoska,et al. Allelic loss of 8p sequences in prostatic intraepithelial neoplasia and carcinoma. , 1997, Urology.
[441] D. Bostwick,et al. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. , 1997, Cancer research.
[442] J Isola,et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. , 1997, Cancer research.
[443] R L Vessella,et al. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[444] L. Liotta,et al. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. , 1996, Cancer research.
[445] G. Buchanan,et al. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[446] D. S. Coffey,et al. Telomerase activity: a prevalent marker of malignant human prostate tissue. , 1996, Cancer research.
[447] L. Liotta,et al. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. , 1995, Cancer research.
[448] G. Bubley,et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.
[449] R. Matusik,et al. Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[450] Jorma Isola,et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.
[451] P. Scardino,et al. The new american joint committee on cancer and international union against cancer tnm classification of prostate cancer , 1994, Cancer.
[452] J. Moul,et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. , 1994, Cancer research.
[453] T Shiraishi,et al. The frequency of latent prostatic carcinoma in young males: the Japanese experience. , 1994, In vivo.
[454] T. Wheeler,et al. Heterogeneity of prostate cancer in radical prostatectomy specimens. , 1994, Urology.
[455] D. Grignon,et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. , 1994, In vivo.
[456] P. Ruck,et al. Neuroendocrine Differentiation in: Hepatoblastoma An Immunohistochemical Investigation , 1990, The American journal of surgical pathology.
[457] G. Stemmermann,et al. Latent prostatic carcinoma: pathological and epidemiological aspects. , 1989, Japanese journal of clinical oncology.
[458] D. Bostwick,et al. Prostatic intraepithelial neoplasia (PIN). , 1989, Urology.
[459] J. McNeal,et al. Normal histology of the prostate. , 1988, The American journal of surgical pathology.
[460] S. J. Higgins,et al. The endocrinology and developmental biology of the prostate. , 1987, Endocrine reviews.
[461] R. Santen,et al. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement , 1987, The Prostate.
[462] G. Evans,et al. Cell proliferation studies in the rat prostate: II. The effects of castration and androgen‐induced regeneration upon basal and secretory cell proliferation , 1987, The Prostate.
[463] D. S. Coffey,et al. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. , 1981, Cancer research.
[464] J. McNeal. The zonal anatomy of the prostate , 1981, The Prostate.
[465] J. E. Dunn. Cancer epidemiology in populations of the United States--with emphasis on Hawaii and California--and Japan. , 1975, Cancer research.
[466] C. Huggins,et al. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.
[467] J. McNeal,et al. Origin and development of carcinoma in the prostate , 1969, Cancer.
[468] W. Haenszel,et al. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. , 1968, Journal of the National Cancer Institute.
[469] J. Bailar,et al. The histology and prognosis of prostatic cancer. , 1967, The Journal of urology.
[470] Y. Oshika,et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.